Aclarion Inc
Research Aclarion Inc (ACON) on Bullrun: market cap USD 6.13M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerACON
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryHealth Information Services
- CurrencyUSD
- Market capUSD 6.13M
- Financial periodQ2 2026
- RevenueUSD 25.21K
- Net income-USD 2.75M
- Free cash flow-USD 2.70M
- Gross margin32.9%
Valuation Snapshot
latest market cap is USD 6.13M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 75.73K | -USD 7.23M | -USD 7.19M | 9.0% | -13.61 | USD 12.02M | n/a | USD 12.84M |
| FY2024 | USD 45.72K | -USD 6.99M | -USD 5.28M | -85.2% | -7478.9 | USD 453.66K | USD 777.09K | USD 970.06K |
| FY2023 | USD 75.40K | -USD 4.91M | -USD 3.65M | -0.4% | -79782 | USD 1.02M | USD 1.13M | -USD 728.00K |
| FY2022 | USD 60.44K | -USD 7.07M | n/a | -8.0% | -19.61 | USD 1.47M | n/a | USD 2.23M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.13M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.93M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.82M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.89M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 8.39M | n/a | n/a | n/a |
About Aclarion Inc
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Aclarion Inc's market cap?
Aclarion Inc's market capitalization is USD 6.13M.
What does Aclarion Inc do?
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine.